A carregar...
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
Gemtuzumab ozogamicin (Mylotarg; Pfizer, New York, NY) was the first antibody–drug conjugate to be approved for CD33‐positive acute myeloid leukemia (AML). However, it was voluntarily withdrawn from the US market due to lack of clinical benefit in the confirmatory phase III trial. In 2012, several i...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852000/ https://ncbi.nlm.nih.gov/pubmed/31070776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1500 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|